Analysis of GP73 in patients with HCC as a function of anti-cancer treatment
| Autor: | Mengjun Wang, Anand Mehta, Julie Hafner, Meejin Ahn, Su Hee Kim, Hie-Won Hann, Mary Ann Comunale, Timothy M. Block, Ronald E. Long, Susan Park |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Pathology Carcinoma Hepatocellular Immunoblotting Gastroenterology Article Young Adult Text mining Neoplasm Recurrence Internal medicine Biomarkers Tumor Genetics medicine Carcinoma Humans In patient Young adult Golgi protein Aged business.industry Liver Neoplasms Membrane Proteins General Medicine Middle Aged Prognosis medicine.disease Cancer treatment Treatment Outcome Oncology Female Neoplasm Recurrence Local Post treatment business |
| Zdroj: | Cancer Biomarkers. 7:269-273 |
| ISSN: | 1875-8592 1574-0153 |
| Popis: | In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|